ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure’s Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company’s next CEO.

瑞士ROOT——（商业新闻短讯）——Novocure（纳斯达克：NVCR）今天宣布，首席执行官（CEO）Asaf Danziger将于2024年底退休，Novocure首席财务官（CFO）Ashley Cordova将接替他担任公司下一任CEO。

Mr. Danziger, who has served as CEO since 2002, will serve as Senior Advisor into early 2026, and will continue to serve on Novocure’s Board of Directors. These changes will become effective on January 1, 2025.

Danziger先生自2002年起担任首席执行官，将担任高级顾问直至2026年初，并将继续担任Novocure董事会成员。这些变更将于2025年1月1日生效。

“It has been a special honor and one of the greatest privileges of my life to serve as Novocure’s CEO for the last 22 years,” said Mr. Danziger. “I am very proud of the organization we have built starting with just a few people in a preclinical lab to where we stand today - treating thousands of patients living with aggressive forms of cancer.

丹泽格先生说：“在过去的22年里，担任Novocure的首席执行官是我一生中的一项特殊荣誉和最大特权。”。“我为我们建立的组织感到骄傲，从临床前实验室的几个人开始，到我们今天所处的位置-治疗数千名患有侵袭性癌症的患者。

Now, we are poised to expand the potential of Tumor Treating Fields therapy to many more people. I am confident that under Ashley’s leadership Novocure is well positioned to achieve great things.”.

现在，我们准备将肿瘤治疗领域治疗的潜力扩大到更多的人。我相信，在Ashley的领导下，Novocure能够取得巨大成就。”。

“Under Asaf’s leadership, Novocure has grown from its earliest days as a start-up into the successful, global company we see today. Our patient-forward mission is a manifestation of Asaf’s vision,” said William Doyle, Executive Chairman, Novocure. “On behalf of Novocure’s Board of Directors, we are grateful for all of Asaf’s many accomplishments and are excited to welcome Ashley as our next CEO.

Novocure执行主席威廉·道尔（WilliamDoyle）表示：“在Asaf的领导下，Novocure从最初的初创公司成长为今天成功的全球性公司。我们耐心的前进使命体现了Asaf的愿景。”。“我们代表Novocure董事会感谢Asaf取得的所有成就，并很高兴欢迎Ashley担任我们的下一任CEO。

Ashley’s strategic vision, commitment to our mission, and proven track record of operational excellence position her perfectly to drive Novocure’s next stage of growth.”.

Ashley的战略愿景、对我们使命的承诺以及卓越运营的良好记录，使她能够完美地推动Novocure的下一阶段增长。”。

“It has been a professional and personal highlight for me to work hand in hand with Asaf over the past 10 years and I am grateful for his leadership and partnership,” said Ms. Cordova. “Novocure’s mission to extend survival in aggressive forms of cancer is as significant today as it was 20 years ago, and I am excited to take on the role of CEO at this pivotal time as we look to expand the reach of Tumor Treating Fields therapy across multiple solid tumor indications.”.

科尔多瓦女士说：“在过去的10年里，与Asaf携手合作是我职业和个人的一大亮点，我感谢他的领导和合作。”。“Novocure在侵袭性癌症中延长生存期的使命今天与20年前一样重要，我很高兴在这个关键时刻担任首席执行官，因为我们希望扩大肿瘤治疗领域治疗跨越多种实体瘤适应症的范围。”。

The company also announced today that Wilco Groenhuysen will step down as Chief Operating Officer (COO) effective October 1, 2024. Mukund Paravasthu, who joined Novocure in 2020 and currently holds the position of Senior Vice President, Product Development, will expand his current responsibilities and transition into the role of COO..

该公司今天还宣布，Wilco Groenhuysen将于2024年10月1日辞去首席运营官（COO）一职。Mukund Paravasthu于2020年加入Novocure，目前担任产品开发高级副总裁，他将扩大目前的职责，并转变为首席运营官。。

“I would like to personally thank Wilco for his friendship, dedication, and leadership over the last 12 years,” said Mr. Danziger. “Wilco helped shape and build our financial, back office and operations functions, and I am grateful for the enduring impact he made at Novocure.”

丹齐格先生说：“我个人要感谢威尔科在过去12年中的友谊、奉献精神和领导才能。”。“Wilco帮助塑造和建立了我们的财务、后台和运营职能，我很感谢他在Novocure所产生的持久影响。”

About Asaf Danziger

关于Asaf Danziger

Asaf Danziger has served as Novocure’s Chief Executive Officer since 2002 and has been a member of the Board of Directors since 2012. Mr. Danziger was Novocure’s fourth employee, leading the organization from its preclinical development stage through regulatory approvals and product commercialization, growing Novocure into an organization with over $500 million in annual global sales and more than 1,500 employees.

Asaf Danziger自2002年起担任Novocure首席执行官，自2012年起担任董事会成员。Danziger先生是Novocure的第四位员工，从临床前发展阶段开始，通过监管批准和产品商业化，领导该组织，使Novocure成为一家年全球销售额超过5亿美元、员工超过1500人的组织。

Mr. Danziger holds a Bachelor of Science in material engineering from Ben-Gurion University of the Negev, Israel..

Danziger先生拥有以色列内盖夫本古里安大学材料工程理学学士学位。。

About Ashley Cordova

关于Ashley Cordova

Ashley Cordova has served as Novocure’s Chief Financial Officer since September 2020. She is responsible for global oversight of Novocure’s revenue and financial operations, including reimbursement activities, financial reporting, financial planning and analysis, treasury, tax, and investor relations..

AshleyCordova自2020年9月起担任Novocure的首席财务官。她负责全球监督Novocure的收入和财务运营，包括报销活动、财务报告、财务规划和分析、财务、税务和投资者关系。。

Joining Novocure in 2014, Ms. Cordova is a leader who combines strategic vision with emphasis on consistent operational excellence. Throughout her tenure, Ms. Cordova has been integral to building Novocure’s global organization and preparing the company for its next stage of growth. She is a visible and engaged enterprise leader, committed to Novocure’s patient-forward mission.

科尔多瓦女士于2014年加入Novocure，她是一位将战略愿景与一贯卓越运营相结合的领导者。在任职期间，科尔多瓦女士一直致力于建立Novocure的全球组织，并为公司的下一个发展阶段做好准备。她是一位引人注目且敬业的企业领导者，致力于Novocure的耐心前进使命。

Prior to joining Novocure, Ms. Cordova served in various financial roles at Zoetis Inc. from 2012 to 2014 and Pfizer Inc. from 2005 to 2012..

在加入Novocure之前，科尔多瓦女士曾于2012年至2014年在Zoetis Inc.和2005年至2012年在辉瑞公司担任过各种财务职务。。

Ms. Cordova graduated with a bachelor’s degree in music and business from Furman University and earned her International Master of Business Administration from the University of South Carolina. Ms. Cordova currently serves on the Board of Directors of Therabody, Inc.

科尔多瓦女士毕业于弗曼大学音乐与商业学士学位，并获得南卡罗来纳大学国际工商管理硕士学位。科尔多瓦女士目前在Therabody，Inc.董事会任职。

About Novocure

关于Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma.

Novocure是一家全球性肿瘤公司，致力于通过其创新疗法，肿瘤治疗领域的开发和商业化，延长一些最具侵袭性的癌症的生存期。Novocure的商业化产品在某些国家被批准用于治疗成人胶质母细胞瘤，恶性胸膜间皮瘤和胸膜间皮瘤患者。

Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer..

Novocure正在进行或完成临床试验，研究脑转移瘤，胃癌，胶质母细胞瘤，肝癌，非小细胞肺癌，胰腺癌和卵巢癌的肿瘤治疗领域。。

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X (Twitter)..

Novocure总部位于瑞士Root，全球足迹不断扩大，在朴茨茅斯、新罕布什尔州和东京设有区域运营中心，在以色列海法设有研究中心。有关该公司的更多信息，请访问Novocure.com，并在LinkedIn和X（推特）上关注@Novocure。。

Forward-Looking Statements

前瞻性声明

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts.

除了历史事实或现状声明外，本新闻稿可能还包含前瞻性声明。前瞻性声明提供了Novocure目前对未来事件的预期或预测。这些可能包括关于其研究计划的预期科学进展、临床试验进展、潜在产品的开发、临床结果的解释、监管批准的前景、制造发展和能力、其产品的市场前景、覆盖范围、第三方付款人的收款以及其他关于非历史事实的陈述。

You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S.

您可以通过在声明中使用诸如“预期”、“估计”、“预期”、“项目”、“打算”、“计划”、“相信”或其他类似含义的词语和术语来识别其中一些前瞻性声明。由于一般的财务、经济、环境、监管和政治条件以及Novocure面临的其他更具体的风险和不确定性，Novocure的业绩和财务结果可能与这些前瞻性报表中反映的业绩和财务结果存在重大差异，如2024年2月22日提交的10-K表年度报告以及随后提交给美国。

Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law.

证券交易委员会。鉴于这些风险和不确定性，任何或所有这些前瞻性陈述可能被证明是不正确的。因此，您不应依赖任何此类因素或前瞻性陈述。此外，Novocure不打算公开更新任何前瞻性声明，除非法律要求。

Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion..

本文件中的任何前瞻性声明仅在本文件日期起生效。1995年的《私人证券诉讼改革法案》允许进行这种讨论。。